16 results on '"Hussein, Akram"'
Search Results
2. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience
- Author
-
Sukrithan, Vineeth, primary, Armbruster, Heather, additional, Rogers, Sherise, additional, Vogt, Sherry Mori, additional, Grenade, Cassandra, additional, Verschraegen, Claire, additional, Zhou, Ye, additional, Goyal, Ashima, additional, Natwa, Mona, additional, Hussein, Akram, additional, Barr, Hallie, additional, Konate, Dramane, additional, Batdorf, Rochelle, additional, Brown, Andrew, additional, Williams, Bonnie, additional, Zhao, Songzhu, additional, Wei, Lai, additional, Xu, Menglin, additional, Shah, Manisha H., additional, and Konda, Bhavana, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Prevalence of group B Streptococcus colonization in pregnant women and the correspondence of its virulence genes with adverse pregnancy outcome.
- Author
-
Sekeb, Hasan Saad, Hassan, Jabbar S., and Shafiq, Hussein Akram
- Subjects
STREPTOCOCCUS agalactiae ,PREGNANT women ,MICROBIAL virulence ,PREMATURE rupture of fetal membranes ,POLYMERASE chain reaction - Abstract
Background and rationale: Group B Streptococcus (GBS) is a Gram-positive, nonmotile, encapsulated bacterium classified under Lancefield group B antigen. Predominantly found in the gastrointestinal and genitourinary tracts. GBS is a leading cause of invasive bacterial diseases in neonates, including neonatal sepsis, meningitis, septicemia, and pneumonia. Aim: To study the vaginal colonization rate of Streptococcus agalactiae and virulence genes in pregnant women with adverse pregnancy outcome. Methods: A cross-sectional study was designed included 200 pregnant women at 34-37 weeks of gestation. A total of two hundred vaginal swabs were taken from all pregnant women enrolled in this project by the gynecologist. GBS isolated bacteria was evaluated by means of using classical microbiological approaches. After DNA extraction, the isolated GBS strains were screened for the presence of cfb and scpB gene by polymerase chain reaction. Results: Thirty-six (18%) of 200 pregnant women enrolled in this project were positive for group B Streptococcus by culture methods. The majority were 18-36 years old, 20 (20.6%) had a history of abortion, and 10 (9.9%) had rupture membranes of >18 hours. The particular PCR primer detected scpB and cfb genes. The scpB gene was discovered in 17 (47%), whereas the cfb gene was detected in 31 (86%). Conclusion: There is no statistical significance between repeated abortions with the presence of scpB and cfb genes as a virulence factor in GBS while there is statistical significance between the presence of these virulence genes and rupture membranes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Asiatic acid rescues intestinal tissue by suppressing molecular, biochemical, and histopathological changes associated with the development of ulcerative colitis.
- Author
-
Lokman, Maha S., Kassab, Rami B., Salem, Fatma A. M., Elshopakey, Gehad E., Hussein, Akram A., Theyab, Abdulrahman, Alzahrani, Khalid J., Hassan, Khalid E., Alsharif, Khalaf F., Albrakati, Ashraf, Tayyeb, Jehad Z., El-khadragy, Manal, Alkhateeb, Mariam A., Al-Ghamdy, Ali O., Althagafi, Hussam A., Moneim, Ahmed E. Abdel, and El-Hennamy, Rehab E.
- Subjects
NUCLEAR factor E2 related factor ,ULCERATIVE colitis ,SALICYLATES ,GLUTATHIONE peroxidase ,NF-kappa B ,INFLAMMATORY mediators ,GLUTATHIONE reductase - Abstract
Asiatic acid (AA) is a polyphenolic compound with potent antioxidative and anti-inflammatory activities that make it a potential choice to attenuate inflammation and oxidative insults associated with ulcerative colitis (UC). Hence, the present study aimed to evaluate if AA can attenuate molecular, biochemical, and histological alterations in the acetic acid-induced UC model in rats. To perform the study, five groups were applied, including the control, acetic acid-induced UC, UC-treated with 40 mg/kg aminosalicylate (5-ASA), UC-treated with 20 mg/kg AA, and UC-treated with 40 mg/kg AA. Levels of different markers of inflammation, oxidative stress, and apoptosis were studied along with histological approaches. The induction of UC increased the levels of lipid peroxidation (LPO) and nitric oxide (NO). Additionally, the nuclear factor erythroid 2-related factor 2 (Nrf2) and its downstream antioxidant proteins [catalase (CAT), superoxide dismutase (SOD), reduced glutathione (GSH), glutathione peroxidase (GPx), and glutathione reductase (GR)] were down-regulated in the colon tissue. Moreover, the inflammatory mediators [myeloperoxidase (MPO), monocyte chemotactic protein 1 (MCP1), prostaglandin E2 (PGE2), nuclear factor-kappa B (NF-B), tumor necrosis factor-a (TNF-a), and interleukin-1ß (IL-1ß)] were increased in the colon tissue after the induction of UC. Notably, an apoptotic response was developed, as demonstrated by the increased caspase-3 and Bax and decreased Bcl2. Interestingly, AA administration at both doses lessened the molecular, biochemical, and histopathological changes following the induction in the colon tissue of UC. In conclusion, AA could improve the antioxidative status and attenuate the inflammatory and apoptotic challenges associated with UC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Prevalence pattern of multidrug resistant Proteus mirabilis recovered from wound of human and cats in Wasit governorate
- Author
-
null Ammar Mohammed Rashied, null Hamza Abd Salih, null Hawraa Abd Alhassan Salman, null Baneen Alaa Abdullah, null Marwa Hussein Akram, null Mustafa Kazem Obeis, and null Mohammed Sachit Hamza
- Subjects
General Medicine ,Proteus mirabilis ,Human ,Cat ,Api20E ,Antibiotics - Abstract
The current work was conducted for isolation and identification ofProteus mirabilisfrom humans and cats. A total of one hundred and fifty samples were collected from hospitals of wasit city during the period from 23/7/2021 to 13/1/2022. These clinical samples included: (90) wound swabs from humans While the total number of samples amount to wound swabs in cats (60). These samples of humans were collected from Al- Zahra Teaching Hospital in wasit and the samples of cats is collected from different places. All isolatesProteus mirabiliswere characterized according to the morphology and microscopic characteristics, along with the biochemical and confirmatory APi 20 E tests. These isolates were obtained from: humans (15) and cats (11).Then determination of antibiotics susceptibility pattern of recovered isolates. The human isolates showed resistant 100 % to Ampicillin, Penicillin, Trimethoprim-Sulfamethoxazole, Streptomycin, Chloramphenicol, Amoxicillin / clavulanic acid, Erythromycin, Tetracycline, Cefoxitin and Vancomycin. Sensitive (100%) for Gentamycin and Ofloxacin. otherwise the cat’s isolates showed resistant (100%) to Ampicillin, Penicillin, Trimethoprim-Sulfamethoxazole, Streptomycin, Chloramphenicol, Amoxicillin / clavulanic acid, Erythromycin, Tetracycline, Ofloxacin, Cefoxitin and Vancomycin. Sensitive (100%) for Gentamycin only.
- Published
- 2023
- Full Text
- View/download PDF
6. Pharmacovigilance in hospice/palliative care: Net effect of amitriptyline or nortriptyline on neuropathic pain: UTS/IMPACCT Rapid programme international consecutive cohort
- Author
-
Hussein, Akram, primary, Digges, Madeline, additional, Chang, Sungwon, additional, Hunt, Jane, additional, Doogue, Matt, additional, Rowett, Debra, additional, Agar, Meera, additional, Sinnarajah, Aynharan, additional, Kain, Danielle, additional, Allan, Simon, additional, Boland, Jason W, additional, and Currow, David C, additional
- Published
- 2022
- Full Text
- View/download PDF
7. DETECTION OF sopB GENE AND BIOFILM FORMATION OF SALMONELLA TYPHI ISOLATED FROM PATIENTS WITH CHOLECYSTITIS.
- Author
-
Shafiq, Hussein Akram, Hassan, Jabbar S., and Shakir, Sinaa Mahdi
- Subjects
SALMONELLA enterica ,AEROBIC bacteria ,CHOLECYSTITIS ,EXOCYTOSIS ,BIOFILMS - Abstract
Salmonella enterica serotypes is a Gram-negative, rod shape, flagellated and aerobic bacteria; it is posing a high risk to human health, particularly in low and middle income countries. Salmonella outer protein B (SopB) was found to interact with secretory pathway that important to provide the nutrients for Salmonella replication and also block the exocytosis. The aim of the study is to determine the rate of occurrence of SopB gene and biofilm formation for Salmonella enterica ser. Typhi isolated from blood of patients with Cholecystitis. 5 ml of one hundred leftover blood sample were immediately transferred to aerobic BacT/ALERT® Culture Media; bottles were vented five seconds then incubated in the BacT/Alert incubator unit for 24 hours according to the manufactured instructions. Positive culture that indicated by color changes were processed by Gram stain, then subcultured on XLD and MacConkey agar, Biofilm formation was assessed by using Microtiter dish biofilm formation assay. Bacterial DNA extraction using a ready commercial kit, a specific pair of primers was used in conventional PCR to detect the presence of sopB gene of Salmonella typhi. Out of 30 of cases showed growth, positive blood culture Salmonella typhi 17 (56.7%) were males while, 13 (43.3%) females; there were 24(80%) out of 30 Salmonella typhi isolates were biofilm producers; almost all S. typhi isolates were positive for sopB gene (93.3%); there are 20 (100%) patients with Cholecystitis were positive result for sopB gene, while 8 (80%) patients without Cholecystitis were positive result for sopB gene. 2 (20%) of patients without Cholecystitis were negative result for sopB gene. In conclusion, SopB gene may plays a significant role in the process of cholecystitis in typhoidal patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
8. First real-world experience of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) since US FDA approval.
- Author
-
Konda, Bhavana, primary, Rogers, Sherise C., additional, Grenade, Cassandra Natalie, additional, Verschraegen, Claire F., additional, Zhou, Ye, additional, Goyal, Ashima, additional, Natwa, Mona, additional, Wright, Chadwick, additional, Hussein, Akram, additional, Barr, Hallie, additional, Konate, Dramane, additional, Brown, Andrew, additional, Batdorf, Rochelle, additional, Williams, Bonnie, additional, Zhao, Songzhu, additional, Wei, Lai, additional, and Shah, Manisha H., additional
- Published
- 2019
- Full Text
- View/download PDF
9. Pharmacovigilance in Hospice/Palliative Care: Net Effect of Haloperidol for Nausea or Vomiting
- Author
-
Digges, Madeline, primary, Hussein, Akram, additional, Wilcock, Andrew, additional, Crawford, Gregory B., additional, Boland, Jason W., additional, Agar, Meera R., additional, Sinnarajah, Aynharan, additional, Currow, David C., additional, and Johnson, Miriam J., additional
- Published
- 2018
- Full Text
- View/download PDF
10. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for nausea or vomiting
- Author
-
Digges, Madeline, Hussein, Akram, Wilcock, Andrew, Crawford, Gregory B., Boland, Jason W., Agar, Meera R., Sinnarajah, Aynharan, Currow, David C., Johnson, Miriam J., Digges, Madeline, Hussein, Akram, Wilcock, Andrew, Crawford, Gregory B., Boland, Jason W., Agar, Meera R., Sinnarajah, Aynharan, Currow, David C., and Johnson, Miriam J.
- Abstract
Background: Haloperidol is widely prescribed as an antiemetic in patients receiving palliative care, but there is limited evidence to support and refine its use. Objective: To explore the immediate and short-term net clinical effects of haloperidol when treating nausea and/or vomiting in palliative care patients. Design: A prospective, multicenter, consecutive case series. Setting/Subjects: Twenty-two sites, five countries: consultative, ambulatory, and inpatient services. Measurements: When haloperidol was started in routine care as an antiemetic, data were collected at three time points: baseline; 48 hours (benefits); day seven (harms). Clinical effects were assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE). Results: Data were collected (May 2014–March 2016) from 150 patients: 61% male; 86% with cancer; mean age 72 (standard deviation 11) years and median Australian-modified Karnofsky Performance Scale 50 (range 10–90). At baseline, nausea was moderate (88; 62%) or severe (11; 8%); 145 patients reported vomiting, with a baseline NCI CTCAE vomiting score of 1.0. The median (range) dose of haloperidol was 1.5 mg/24 hours (0.5–5 mg/24 hours) given orally or parenterally. Five patients (3%) died before further data collection. At 48 hours, 114 patients (79%) had complete resolution of their nausea and vomiting, with greater benefit seen in the resolution of nausea than vomiting. At day seven, 37 (26%) patients had a total of 62 mild/moderate harms including constipation 25 (40%); dry mouth 13 (21%); and somnolence 12 (19%). Conclusions: Haloperidol as an antiemetic provided rapid net clinical benefit with low-grade, short-term harms.
- Full Text
- View/download PDF
11. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for nausea or vomiting
- Author
-
Digges, Madeline, Hussein, Akram, Wilcock, Andrew, Crawford, Gregory B., Boland, Jason W., Agar, Meera R., Sinnarajah, Aynharan, Currow, David C., Johnson, Miriam J., Digges, Madeline, Hussein, Akram, Wilcock, Andrew, Crawford, Gregory B., Boland, Jason W., Agar, Meera R., Sinnarajah, Aynharan, Currow, David C., and Johnson, Miriam J.
- Abstract
Background: Haloperidol is widely prescribed as an antiemetic in patients receiving palliative care, but there is limited evidence to support and refine its use. Objective: To explore the immediate and short-term net clinical effects of haloperidol when treating nausea and/or vomiting in palliative care patients. Design: A prospective, multicenter, consecutive case series. Setting/Subjects: Twenty-two sites, five countries: consultative, ambulatory, and inpatient services. Measurements: When haloperidol was started in routine care as an antiemetic, data were collected at three time points: baseline; 48 hours (benefits); day seven (harms). Clinical effects were assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE). Results: Data were collected (May 2014–March 2016) from 150 patients: 61% male; 86% with cancer; mean age 72 (standard deviation 11) years and median Australian-modified Karnofsky Performance Scale 50 (range 10–90). At baseline, nausea was moderate (88; 62%) or severe (11; 8%); 145 patients reported vomiting, with a baseline NCI CTCAE vomiting score of 1.0. The median (range) dose of haloperidol was 1.5 mg/24 hours (0.5–5 mg/24 hours) given orally or parenterally. Five patients (3%) died before further data collection. At 48 hours, 114 patients (79%) had complete resolution of their nausea and vomiting, with greater benefit seen in the resolution of nausea than vomiting. At day seven, 37 (26%) patients had a total of 62 mild/moderate harms including constipation 25 (40%); dry mouth 13 (21%); and somnolence 12 (19%). Conclusions: Haloperidol as an antiemetic provided rapid net clinical benefit with low-grade, short-term harms.
- Full Text
- View/download PDF
12. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for nausea or vomiting
- Author
-
Digges, Madeline, Hussein, Akram, Wilcock, Andrew, Crawford, Gregory B., Boland, Jason W., Agar, Meera R., Sinnarajah, Aynharan, Currow, David C., Johnson, Miriam J., Digges, Madeline, Hussein, Akram, Wilcock, Andrew, Crawford, Gregory B., Boland, Jason W., Agar, Meera R., Sinnarajah, Aynharan, Currow, David C., and Johnson, Miriam J.
- Abstract
Background: Haloperidol is widely prescribed as an antiemetic in patients receiving palliative care, but there is limited evidence to support and refine its use. Objective: To explore the immediate and short-term net clinical effects of haloperidol when treating nausea and/or vomiting in palliative care patients. Design: A prospective, multicenter, consecutive case series. Setting/Subjects: Twenty-two sites, five countries: consultative, ambulatory, and inpatient services. Measurements: When haloperidol was started in routine care as an antiemetic, data were collected at three time points: baseline; 48 hours (benefits); day seven (harms). Clinical effects were assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE). Results: Data were collected (May 2014–March 2016) from 150 patients: 61% male; 86% with cancer; mean age 72 (standard deviation 11) years and median Australian-modified Karnofsky Performance Scale 50 (range 10–90). At baseline, nausea was moderate (88; 62%) or severe (11; 8%); 145 patients reported vomiting, with a baseline NCI CTCAE vomiting score of 1.0. The median (range) dose of haloperidol was 1.5 mg/24 hours (0.5–5 mg/24 hours) given orally or parenterally. Five patients (3%) died before further data collection. At 48 hours, 114 patients (79%) had complete resolution of their nausea and vomiting, with greater benefit seen in the resolution of nausea than vomiting. At day seven, 37 (26%) patients had a total of 62 mild/moderate harms including constipation 25 (40%); dry mouth 13 (21%); and somnolence 12 (19%). Conclusions: Haloperidol as an antiemetic provided rapid net clinical benefit with low-grade, short-term harms.
- Full Text
- View/download PDF
13. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for nausea or vomiting
- Author
-
Digges, Madeline, Hussein, Akram, Wilcock, Andrew, Crawford, Gregory B., Boland, Jason W., Agar, Meera R., Sinnarajah, Aynharan, Currow, David C., Johnson, Miriam J., Digges, Madeline, Hussein, Akram, Wilcock, Andrew, Crawford, Gregory B., Boland, Jason W., Agar, Meera R., Sinnarajah, Aynharan, Currow, David C., and Johnson, Miriam J.
- Abstract
Background: Haloperidol is widely prescribed as an antiemetic in patients receiving palliative care, but there is limited evidence to support and refine its use. Objective: To explore the immediate and short-term net clinical effects of haloperidol when treating nausea and/or vomiting in palliative care patients. Design: A prospective, multicenter, consecutive case series. Setting/Subjects: Twenty-two sites, five countries: consultative, ambulatory, and inpatient services. Measurements: When haloperidol was started in routine care as an antiemetic, data were collected at three time points: baseline; 48 hours (benefits); day seven (harms). Clinical effects were assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE). Results: Data were collected (May 2014–March 2016) from 150 patients: 61% male; 86% with cancer; mean age 72 (standard deviation 11) years and median Australian-modified Karnofsky Performance Scale 50 (range 10–90). At baseline, nausea was moderate (88; 62%) or severe (11; 8%); 145 patients reported vomiting, with a baseline NCI CTCAE vomiting score of 1.0. The median (range) dose of haloperidol was 1.5 mg/24 hours (0.5–5 mg/24 hours) given orally or parenterally. Five patients (3%) died before further data collection. At 48 hours, 114 patients (79%) had complete resolution of their nausea and vomiting, with greater benefit seen in the resolution of nausea than vomiting. At day seven, 37 (26%) patients had a total of 62 mild/moderate harms including constipation 25 (40%); dry mouth 13 (21%); and somnolence 12 (19%). Conclusions: Haloperidol as an antiemetic provided rapid net clinical benefit with low-grade, short-term harms.
- Full Text
- View/download PDF
14. Pharmacovigilance in hospice/palliative care: net effect of amitriptyline or nortriptyline on neuropathic pain: UTS/IMPACCT Rapid programme international consecutive cohort
- Author
-
Akram Hussein, Madeline Digges, Sungwon Chang, Jane Hunt, Matt Doogue, Debra Rowett, Meera Agar, Aynharan Sinnarajah, Danielle Kain, Simon Allan, Jason W Boland, David C Currow, Hussein, Akram, Digges, Madeline, Chang, Sungwon, Hunt, Jane, Doogue, Matt, Rowett, Debra, Agar, Meera, Sinnarajah, Aynharan, Kain, Danielle, Allan, Simon, Boland, Jason W, and Currow, David C
- Subjects
neuropathic pain ,Amitriptyline ,Palliative Care ,Hospices ,General Medicine ,Nortriptyline ,amitriptyline ,Antidepressive Agents, Tricyclic ,nortriptyline ,Pharmacovigilance ,Anesthesiology and Pain Medicine ,pharmacovigilance ,post-marketing surveillance ,1117 Public Health and Health Services, 1199 Other Medical and Health Sciences ,cohort study ,Humans ,Neuralgia ,Prospective Studies ,Gerontology ,Aged - Abstract
Background: Real-world effectiveness of interventions in palliative care need to be systematically quantified to inform patient/clinical decisions. Neuropathic pain is prevalent and difficult to palliate. Tricyclic antidepressants have an established role for some neuropathic pain aetiologies, but this is less clear in palliative care. Aim: To describe the real-world use and outcomes from amitriptyline or nortriptyline for neuropathic pain in palliative care. Design: An international, prospective, consecutive cohort post-marketing/phase IV/pharmacovigilance/quality improvement study of palliative care patients with neuropathic pain where the treating clinician had already made the decision to use a tricyclic antidepressant. Data were entered at set times: baseline, and days 7 and 14. Likert scales graded benefits and harms. Setting/participants: Twenty-one sites (inpatient, outpatient, community) participated in six countries between June 2016 and March 2019. Patients had clinician-diagnosed neuropathic pain. Results: One hundred and fifty patients were prescribed amitriptyline (110) or nortriptyline (40) of whom: 85% had cancer; mean age 73.2 years (SD 12.3); mean 0–4 scores for neuropathic pain at baseline were 1.8 (SD 1.0). By day 14, doses of amitriptyline were 57 mg (SD 21) and nortriptyline (48 mg (SD 21). Fifty-two (34.7%) patients had pain improvement by day 14 (amitriptyline (45/110 (43.3%); nortriptyline (7/40 (18.9%)). Thirty-nine (27.7%) had new harms; (amitriptyline 29/104 (27.9%); nortriptyline 10/37 (27.0%); dizziness ( n = 23), dry mouth ( n = 20), constipation ( n = 14), urinary retention ( n = 10)). Benefits without harms occurred (amitriptyline (26/104 (25.0%); nortriptyline (4/37 (10.8%)). Conclusions: Benefits favoured amitriptyline while harms were similar for both medications.
- Published
- 2022
15. Estudio comparativo de la percepción del ambiente educacional en 5 Facultades de Odontología
- Author
-
Felipe Spada, Natalia, Alí Hussein, Akram, Arregui Gambús, María, and Universitat Internacional de Catalunya. Departament d'Odontologia
- Subjects
Estudiantes ,DREEM ,Odontología preventiva ,Ambiente educativo ,Odontología ,616.3 - Abstract
Objetivo: Determinar el ambiente educacional (AE) de cinco Facultades de Odontología (dos Europeas y tres Americanas). Material y métodos: Se aplicó el cuestionario Dundee Ready Education Environment Measure (DREEM) a un grupo de alumnos de todos los cursos de grado de cinco Facultades de Odontología. Resultados: Un total de 1826 cuestionarios correctamente cumplimentados fueron analizados, donde 536 fueron hombres y 1290 mujeres. El índice de participación fue de 70,9%. La media de edad de los participantes fue de 21,28 3,26 años. El valor del AE de las cinco Universidades fue de 127,44 puntos y para cada uno de los cinco dominios fue el siguiente: Aprendizaje 37,45/48; Profesorado 27,68/44, Académico 22,10/32; Atmósfera 28,49/48 y Social 17,79/28. Se detectaron diferencias estadísticamente significativas en la valoración de algunos ítems entre géneros. Se evidenciaron puntos problemáticos que requieren intervención. Conclusiones: la percepción del AE es más positivo que negativo en las cinco Facultades sin presentar diferencias estadísticamente significativas entre ellas. La interpretación de los dominios es la misma para todas las Facultades excepto en una de ellas en la que el dominio que valora la atmósfera se interpreta como que hay muchos aspectos que necesitan ser modificados debido a su baja puntuación.
- Published
- 2017
16. Influencia de los antioxidantes, ascorbato de sodio y alfa tocoferol, en la fuerza de adhesión a esmalte previamente blanqueado con dentífricos blanqueadores
- Author
-
Fenoy Illacer, María del Pilar, Vallés Rodríguez, Marta, Alí Hussein, Akram, and Universitat Internacional de Catalunya. Departament d'Odontologia
- Subjects
616.3 ,Odontologia - Abstract
El objetivo de nuestro trabajo es determinar si el blanqueamiento dental puede disminuir los valores de adhesión a esmalte, valorar como influyen los distintos tiempos de espera para los procedimientos adhesivos tras el blanqueamiento dental, la capacidad de ascorbato de sodio de revertir la disminución de los valores de adhesión, así como valorar si los dentífricos blanqueadores tienen la capacidad de afectar la posterior adhesión sobre la superficie dental, disminuyendo la resistencia adhesiva y evaluar si la aplicación de antioxidantes tras el uso de dentífricos blanqueadores y previamente al procedimiento adhesivo revierte la disminución de los valores de adhesión provocada por el tratamiento blanqueador. En nuestro primer estudio se observó cómo afecta el blanqueamiento de alta concentración en la adhesión, así como la influencia de los distintos tiempos de espera tras el blanqueamiento dental, previamente al procedimiento adhesivo.Por ello, en nuestro primer estudio se observó cómo afectaba el tratamiento de blanqueamiento dental con peróxido de hidrógeno al 40% a los valores de adhesión a esmalte, la influencia de los distintos tiempos de espera tras el blanqueamiento, previamente al procedimiento adhesivo, así como la capacidad de ascorbato de sodio de aumentar los valores de adhesión. En la literatura encontramos multitud de estudios de investigación que evalúan la adhesión tras realizar tratamientos de blanqueamiento con productos de alta concentración (blanqueamiento en clínica y ambulatorio), pero en el inicio de esta tesis, no encontramos ningún estudio de investigación que evalúe como se afecta la adhesión tras el uso de pastas blanqueadoras y el efecto de la aplicación de antioxidantes. En nuestro segundo estudio se pretendía estudiar si la adhesión se podía afectar tras el uso de 2 diferentes pastas blanqueadoras y determinar si la aplicación de antioxidantes podía revertir este efecto, los antioxidantes elegidos, tras una revisión de la literatura, fueron ascorbato de sodio y alfa tocoferol. Al observar que la adhesión se veía afectada únicamente con una de las pastas dentífricas blanqueadoras, se decidió seguir profundizando en nuestra investigación y utilizar diferentes pastas blanqueadoras. En nuestro tercer estudio utilizamos cinco pastas dentífricas blanqueadoras diferentes, con composiciones distintas, de las cuales alguna tenía en su composición peróxido y la mayoría de las pastas dentífricas realizaban su acción blanqueadora mediante abrasivos, con el objetivo de determinar si se veía comprometida la adhesión tras el uso de las mismas.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.